louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05036031: Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
Official title: Liver Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study to Evaluate Different Criterion in Predicting Post-transplant Outcomes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute-On-Chronic Liver Failure
Liver Cirrhosis
Liver Transplant; Complications
Keywords: Acute-On-Chronic Liver Failure
EASL-CLIF criteria
APASL criteria
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2021-09-05
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients underwent liver transplantation for cirrhosis at Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China between January 2015 and June 2020 were considered for inclusion.

Brief summary: The definition and diagnostic criteria of acute-on chronic liver failure (ACLF) differed evidently between the East and the West due to the difference in the underlying etiology. Liver transplantation is the most effective treatment to reverse the progress of ACLF and improve the survival rate of patients. The purpose of this study is to explore the accuracy of the two diagnostic criteria of EASL-CLIF and APASL ACLF in assessing the survival rate of patients with liver cirrhosis after LT.

Detailed description: A retrospective collection and analysis of the preoperative conditions of patients with LT due to cirrhosis in a single center from January 2015 to June 2020 would be conducted, including epidemiological characteristics, etiology, clinical indicators, and short-term (28 days, 90 days) and long-term (1 year, 3 years) survival after LT.

Eligibility criteria: Inclusion Criteria:

* patients underwent liver transplantation for cirrhosis
* The diagnosis of ACLF followed APASL and EASL-CLIF definition.

Exclusion Criteria:

* Patients with malignant tumor or underwent living donor liver transplantation (LDLT) were excluded.

Primary outcomes:
measure: 3 years overall survival
timeFrame: Up to ~3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
name: Qiang Xia
role: STUDY_CHAIR
affiliation: Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
name: Hao Feng
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00856531: Impairments of Oral Language in Mobius Syndrome
Official title: Impairments of Oral Language in Subjects With the Möbius Sequence
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Möbius Sequence
Keywords: Möbius syndrome
Language
Speech, Language and Hearing Sciences
Lead sponsor: Fortaleza University
Sponsor class: OTHER
First posted: 2009-03-05
Sex: ALL
Minimum age (years): 3
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: fifteen subjects with Möbius syndrome with age ranging from two to thirteen years old, from both sexes, seen in one of the three main center for genetic diagnosis in the state of Ceará, Brazil.

Brief summary: The Möbius syndrome constitutes a congenital disorder classically caused by genetic and environmental factors. The clinical manifestations include lesion of the facial and abducens nerves associated with limb malformations specially club foot. The speech-language manifestations include compromise of oral and deglutition, speech and language functions, secondary to cranial nerves lesions and mental retardation. The language compromise in this disorder is still not well known. In this way, the main objective of this study is to characterize the oral language in a population of fifteen subjects with Möbius syndrome with age ranging from two to thirteen years old, from both sexes, seen in one of the three main center for genetic diagnosis in the state of Ceará. The present work is a descriptive study of a cross-sectional design conducted from February to December/2002, using a clinical evaluation of language components including morphology, syntax, semantics and pragmatics. The investigators identified exclusive speech involvement in 20,0% of the subjects, language disturbance in 46,7%, speech and language disturbance in 13,3% and oral language involvement in 26,7%. The investigators conclude that the language disturbance in the Möbius syndrome presents with a variable compromise of all oral language components. The delay in linguistical development, incomprehensive speech and the deficit of constructions of sentences and narrations are constant.

Detailed description: In this way, the main objective of this study is to characterize the oral language in a population of fifteen subjects with Möbius syndrome with age ranging from two to thirteen years old, from both sexes, seen in one of the three main center for genetic diagnosis in the state of Ceará. The present work is a descriptive study of a cross-sectional design conducted from February to December/2002, using a clinical evaluation of language components including morphology, syntax, semantics and pragmatics.

Eligibility criteria: Inclusion Criteria:

* Möbius syndrome
* Age ranging from two to thirteen years old.

Exclusion Criteria:

* Others diseases with impact in oral language.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05929131: Video and Brochure and Discharge Instructions for Childhood Fever in the Pediatric Emergency Department
Official title: Video and Brochure and Discharge Instructions for Childhood Fever in the Pediatric Emergency Department
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fever
Child, Only
Lead sponsor: Bartın Unıversity
Sponsor class: OTHER
First posted: 2023-07-03
Enrollment: 144
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: OTHER

Brief summary: This study was designed to evaluate whether adding Video discharge instructions to usual verbal information improves understanding of the information provided to caregivers of patients presenting to pediatric emergency departments for high fever. As secondary goals, it was aimed to assess whether video discharge instructions increase satisfaction with information received and reduce repeat visits.

Detailed description: The research will be carried out in a randomized controlled manner. There will be three groups in the research: those who received video (intervention), brochure (intervention) and verbal (control) discharge instructions. A power analysis was performed based on the number of children in both groups, in another study in which the scales to be used in the research were used. According to the calculations made in the G-Power 3.1 Demo package program, when the effect size was accepted as 0.8, it was seen that at least 48 cases in each group would be sufficient for 80% power. Children who meet the research criteria will be assigned a random number to the intervention and control groups via http://www.randomize.org/ by numbering the order of arrival at the hospital. Research data will be collected using Descriptive Information Form and Parental Fever Management Scale and Post-Discharge Data Collection Form.

Eligibility criteria: Inclusion Criteria:

* The child is between 1 month and 18 years old
* Parent's consent to participate in the research
* Parent's completion of all pre-and post-education follow-up

Exclusion Criteria:

* The child is not between 1 month and 18 years old
* The child does not undergo day surgery.
* Parent's refusal to participate in the research
* Parent not completing all pre- and post-education follow-up

Primary outcomes:
measure: The parents in the groups who received discharge instructions with a video and brochure, three days later, had a lower "Parental Fever Management Scale" score average than the control group.
timeFrame: 3 days
Secondary outcomes:
measure: The parents in the groups who received discharge instructions with a video and brochure, after three days, had higher scores on the "Fever Management Approach Scale" compared to the control group.
timeFrame: 3 days
Other outcomes:
Locations:
city: Bartın
country: Turkey
facility: Bartin Maternity and Pediatrics Hospital
Study officials:
References:
Clinical trial NCT00734331: Micro Ribonucleic Acid (RNA) as Cholinergic Tone and Inflammatory Regulator in Inflammatory Bowel Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inflammatory Bowel Disease
Keywords: inflammatory bowel disease
micro RNA
cholinergic tone
inflammation
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
Collaborators: name: Hebrew University of Jerusalem
First posted: 2008-08-14
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients- inflammatory bowel disease patients under going colonoscopy controls- average risk patients without inflammation under going colonoscopy

Brief summary: There is a reciprocal relationship between the central nervous system and the immune system. Stimulation of the vagus nerve results in secretion of acetylcholine (Ach) which decreases secretion of pro-inflammatory cytokines. Acetylcholine esterase is an enzyme that neutralizes Ach and thus, involves in regulation of Ach levels, and in the cholinergic tone and inflammatory state.

MicroRNAs (miRs) are evolutionarily conserved, RNAs that regulate gene expression. The investigators hypothesized that miRs controlling systemic communication processes function in one tissue in response to signals (i.e. neuronal, hormonal or others) from another.

Specifically, the investigators hypothesized that miRs control the inflammatory response in inflammatory bowel diseases through regulation of expression of messenger RNA of AchE.


Eligibility criteria: Inclusion Criteria:

* Inflammatory bowel disease patients under going colonoscopy

Exclusion Criteria:

* Debilitated patients who need an apotropsy
* Age \< 18 or age \> 75
* Pregnant women
* Evidence of previous or current cancer
* Inflammatory disease other than IBD

Primary outcomes:
measure: Elevated expression of specific micro RNAs that regulate the expression of the enzyme Acetylcholine esterase in inflammatory bowel disease patients compared to healthy controls.
timeFrame: one year
Secondary outcomes:
measure: A statistically significant relation between micro RNA expression and disease activity and inflammatory indices
timeFrame: one year
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center
Study officials:
References:
Clinical trial NCT04792931: Adult Autoimmune Myopathies (MAIA)
Official title: Adult Autoimmune Myopathies (MAIA): Clinical and Immunological Characterization, Constitution of a Patient Library
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Idiopathic Inflammatory Myopathies
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2021-03-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: diagnosis and follow up of adult autoimmune myopathies
Primary purpose: DIAGNOSTIC

Brief summary: This study corresponds to a monocentric prospective cohort of adult patients presenting a suspicion of idiopathic inflammatory myopathy. It will allows the constitution of an organized collection of longitudinal clinical data as well as collection of biological samples, including blood sample, urine, stool and muscle specimen.


Eligibility criteria: Inclusion Criteria:

* Clinical suspicion of Adult Inflammatory Myopathy
* Social security affiliation

Exclusion Criteria:

* Pregnant and lactating women
* Patients unable to consent
* Patients refusing to participate in the research.
* Patients under legal protection

Primary outcomes:
measure: Distribution of lymphocytes subpopulations (B, T and TH-17)
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHU de BREST
Study officials:
References:
Clinical trial NCT03518931: Understanding Fitness' Function in Determining Activity
Official title: Understanding Fitness' Function in Determining Activity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise
Fitness
Strength
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2018-05-08
Enrollment: 1315
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of the study is to determine how measuring strength (by squeezing a tool called a hand grip dynamometer) and cardiorespiratory fitness (by climbing stairs) and sharing the results with subjects impacts exercise.

Detailed description: The Understanding Fitness Function in Determining Activity (UFFDA) Study was initiated at the 2014 and 2015 Minnesota State Fair to determine if measuring muscular strength and CRF would motivate individuals to increase their physical activity. Eligible individuals consented to participate and were randomized in a 1:1 allocation to control or intervention groups. All participants provided their current Exercise Vital Sign (EVS calculated by multiplying the number of moderate-vigorous exercise sessions/week by the average minutes/session). The intervention group had VO2max estimated using a timed previously validated Step Test and muscular strength measured using a Hand Dynamometer. Results with age appropriate normative data for both grip strength and a "good or superior" VO2max were provided to the intervention group. Our hypothesis was participants who receive the intervention would increase physical activity (measured by EVS) compared to control participants.

Eligibility criteria: Inclusion Criteria:

Greater then 18 years old and able to complete the 20-step test to estimate CRF.

Exclusion Criteria:

History of heart disease, Syncope, Chest pain, Dyspnea, Use of beta blockers, Use of non-dihydropyridine calcium channel blockers, Evidence of any unstable medical conditions. Pregnant

Primary outcomes:
measure: Exercise vital sign
timeFrame: Baseline to 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Minnesta
name: Andrew Olson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Langland JT, Sathnur N, Wang Q, Olson APJ. Do assessments of cardiorespiratory and muscular fitness influence subsequent reported physical activity? A randomized controlled trial. BMC Sports Sci Med Rehabil. 2021 Jun 15;13(1):69. doi: 10.1186/s13102-021-00295-z.
Clinical trial NCT06362031: A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
Official title: A Center-Based Chart Review Study to Assess Treatment Outcomes of Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Acute Myeloid Leukemia
Keywords: Acute Myeloid Leukemia
Cancer
Venetoclax: Venclyxto
ABT-199
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2024-04-12
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult Participants with Acute Myeloid Leukemia (AML) being treated with venetoclax.

Brief summary: Acute myeloid leukemia (AML), also referred to as acute myelogenous leukemia or acute non-lymphocytic leukemia, is a relatively rare, yet aggressive, type of cancer. This study will evaluate treatment patterns, treatment outcomes, healthcare resource utilization in adult participants with AML receiving venetoclax.

Data from up to 700 participants will be collected. No participants will be enrolled in this study.

Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 10 months.

There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 10 months.


Eligibility criteria: Inclusion Criteria:

* The participant received a diagnosis for acute myeloid leukemia (AML).
* The participant was initiated on the studied line of therapy for previously untreated AML, as noted in the protocol.
* The participant was treated with the studied line of therapy at least 28 days prior to date of data collection.
* Information on the participant's treatments, selected (or important) clinical characteristics, and outcomes is available from the start of the studied line of therapy onwards.

Exclusion Criteria:

* The participant received the studied line of therapy as part of a clinical trial.
* Participant received prior lines of therapy for AML.
* The participant has a history of malignancies within 2 years prior to the studied line of therapy, other than AML, and with the exception of what is noted in the protocol.

Primary outcomes:
measure: Overall Survival (OS)
timeFrame: Up to 10 Months
measure: Event-free survival (EFS)
timeFrame: Up to 10 Months
measure: Percentage of Participants Achieving Best Overall Response
timeFrame: Up to 10 Months
measure: Duration of Response (DoR)
timeFrame: Up to 10 Months
measure: Percentage of Participants with Transfusion Independence (TI)
timeFrame: Up to 10 Months
Secondary outcomes:
measure: Number of Participants with Healthcare Resource Utilization (HRU)
timeFrame: Up to 10 Months
Other outcomes:
Locations:
Study officials:
affiliation: AbbVie
name: ABBVIE INC.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06905431: Effects of Plyometric and High Intensity Interval Training on Sprint Speed, Agility and Power Among Female Fast Bowlers
Official title: Effects of Plyometric and High Intensity Interval Training on Sprint Speed, Agility and Power Among Female Fast Bowlers
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Health Knowledge, Attitudes, Practice
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2025-04-01
Enrollment: 35
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will investigate the comparative effects of plyometric training (PT) and high-intensity interval training (HIIT) on key performance metrics: sprint speed, agility, and power. The research will be conducted as a randomized clinical trial over six months, involving 34 participants recruited from cricket academies.

Detailed description: Participants will be randomly assigned to either the PT or HIIT group. The PT group will perform exercises leveraging the stretch-shortening cycle to enhance explosive power, while the HIIT group will alternate high-intensity activity with recovery periods to improve anaerobic capacity. Standardized tools, including the 40-Yard Sprint Test, Standing Broad Jump, and Agility T-Test, will be used to assess outcomes pre- and post-intervention. Data will be analyzed using SPSS, employing paired t-tests and Mann-Whitney U tests for within- and between-group comparisons

Eligibility criteria: Inclusion Criteria:

* Female fast bowlers age 18-25 years
* Active cricketers with at least 2 years of experience in fast bowling (20)
* Active health status, no history of severe injuries

Exclusion Criteria:

* Any history of chronic injuries, musculoskeletal disorders, or conditions that could be exacerbated by high-intensity exercise.
* Participants not regularly training or competing in cricket.
* Females underwent C-section and or having two children will exclude

Primary outcomes:
measure: 40 Yard Sprint Test
timeFrame: 12 Months
measure: Standing Broad Jump (SBJ)
timeFrame: 12 Months
measure: Assessment of Agility T-Test
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Punjab university, education university, GCU university
state: Punjab
Study officials:
References:
Clinical trial NCT03229031: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE3
Conditions: Spinal Cord Injuries
Keywords: spinal cord, spinal cord injury
Lead sponsor: Eusol Biotech Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-07-25
Enrollment: 160
Sex: ALL
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To demonstrate the superior effect of ES135 combined with spinal cord repairing surgery, compared to a placebo control with spinal cord repairing surgery, on post-surgery motor function recovery as measured by the changes from baseline of ISNCSCI Motor Scores in subjects


Eligibility criteria: Inclusion Criteria:

1. Subjects of either sex and 15-65 years of age.
2. Subjects have spinal cord injury and the subjects must be categorized as Grade A or B by the ASIA Impairment Scale.
3. Subjects have adequate heart, lung, kidney and liver function.
4. Subjects are able to give voluntary and dated informed consent prior to enrollment.

Exclusion Criteria

1. Penetration SCI
2. Brain damage or multiple injuries
3. History of congenital or acquired abnormalities in the spinal cavity
4. History of congenital or acquired immunodeficiency disorders
5. History of malignancies or positive results
6. Current serious/uncontrollable infections or others serious diseases
7. Pregnant or lactating women
8. Allergy to ES135 or any of its excipients
9. Unable to obtain informed consent from subject

Primary outcomes:
measure: Mean change of International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Motor Scores
timeFrame: 48 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Veterans General Hospital
city: New Taipei City
country: Taiwan
facility: Far Eastern Memorial Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
Study officials:
References: